Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling.
Lu Chen, Ruyu Han, Shujie Zhai et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II trial evaluated tislelizumab monotherapy as a neoadjuvant treatment for 36 patients with resectable early-stage hepatocellular carcinoma (HCC). The study found an objective response rate of 30.6% using modified RECIST criteria, with a major pathological response rate of 33.3% among those who underwent resection. The trial also highlighted the potential of tumor microenvironment profiling in predicting treatment response.
Key findings
- Objective response rates were 13.9% and 30.6% based on different evaluation criteria.
- The major pathological response rate was 33.3% among resected patients.
- Grade ≥ 3 treatment-emergent adverse events occurred in 11.1% of patients.
- A multimodal model achieved an average precision of 0.9167 for identifying sensitive patients.
Why it matters
Understanding the efficacy and safety of neoadjuvant immunotherapy in early-stage HCC can guide treatment decisions and optimize patient outcomes. Predictive modeling may help tailor therapies, reducing unnecessary toxicity from ineffective treatments.